Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Subcutaneous Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for Untreated Indolent B-Cell Non-Hodgkin Lymphoma

NCT05169658 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT05169658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05169658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Subcutaneous Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
March 23, 2022
Completion date
April 2, 2025
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, indolent b-cell non-hodgkin lymphoma, marginal zone lymphoma, non-hodgkin lymphoma, recurrent extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue